MBX Biosciences, Inc.

Equities

MBX

US55287L1017

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
33.77 ^USD	+1.66%		+8.94%	+7.07%

Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Transcript : MBX Biosciences, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03

Published on 01/14/2026 at 02:21 pm EST

S&P Capital IQ

Presenter Speech
Jessica Fye (Analysts)

Great. Good afternoon, everyone. Welcome. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about MBX Biosciences, Inc.

Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Mar. 12	MBX Biosciences Q4 Net Loss Widens; Expects Cash Runway Into 2029	MT
Mar. 12	Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss	MT
Mar. 10	MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer	CI
Mar. 09	MBX Plans Phase 3 Trial of Hypoparathyroidism Drug in Q3	MT
Mar. 09	MBX Biosciences Announces Phase 3 Development Plan For Once-Weekly Canvuparatide For Hypoparathyroidism	CI
Feb. 27	MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief	MT
Feb. 27	MBX Biosciences, Inc. Announces CFO Changes	CI
Jan. 28	Barclays Initiates Coverage on MBX Biosciences With Overweight Rating	MT
Jan. 22	MBX Biosciences, Inc. Announces Board and Committee Changes	CI
Jan. 14	MBX Biosciences, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
Jan. 11	Mbx Biosciences says phase 3 trial of canvuparatide to start in Q3 2026	RE
Jan. 07	UBS Initiates MBX Biosciences at Buy With $60 Price Target	MT
Dec. 21	MBX Biosciences, Inc.(NasdaqGS:MBX) added to S&P Pharmaceuticals Select Industry Index	CI